LoQus23 Advances First-in-Class Oral Drug LQT-23 for Huntington's Disease Treatment
核心洞察
LoQus23 Therapeutics (搜索) has nominated LQT-23 (搜索) as its lead development candidate, representing a first-in-class oral small-molecule inhibitor targeting MSH3 (搜索)/MutS𝛽 (搜索) for Huntington's disease (搜索) treatment.
The drug employs a novel allosteric mechanism to inhibit somatic expansion, addressing the root cause of disease progression rather than downstream toxic proteins.
Preclinical studies demonstrated potent and selective modulation of the target with robust blockade of somatic expansion in Huntington's disease (搜索) cellular systems and animal models.
Cambridge-based LoQus23 Therapeutics (搜索) has nominated LQT-23 (搜索) as its lead development candidate, marking a significant milestone in the pursuit of disease-modifying treatments for Huntington's disease (搜索). The first-in-class oral small-molecule inhibitor targets MSH3 (搜索)/MutS𝛽 (搜索), a protein complex identified as a central driver of disease progression in this fatal inherited neurodegenerative disorder (搜索) that currently has no approved therapies.
Targeting the Root Cause of Disease Progression
Huntington's disease (搜索) is caused by an abnormal expansion of CAG repeats in the huntingtin gene. While individuals inherit a pathogenic repeat length at birth, it is the continued expansion of these repeats in brain cells that ultimately triggers neurodegeneration, typically decades later. This process helps explain the delayed onset of symptoms and has increasingly become a focal point for therapeutic development.
LQT-23 (搜索) is designed to intervene earlier in the disease cascade by suppressing somatic expansion, rather than focusing on downstream toxic proteins. The approach targets MutS𝛽 (搜索), which genetic, post-mortem and mechanistic studies have converged on as one of the most strongly validated targets in this pathway, specifically through its key component MSH3 (搜索).
Breakthrough in Small-Molecule Development
MutS𝛽 (搜索) has long been considered difficult to modulate with small molecules due to its complex structure and biological role. LoQus23 describes LQT-23 (搜索) as representing a significant advance, combining high potency with a novel allosteric mechanism designed to inhibit MutS𝛽 activity.
"The nomination of LQT-23 (搜索) as our development candidate is a significant moment for LoQus23 and reaffirms our strategy of advancing our pipeline of MSH3 (搜索)/MutS𝛽 (搜索) inhibitors to transform the lives of patients," said Dr. David Reynolds, Chief Executive Officer of LoQus23 Therapeutics (搜索). "I want to salute the dedication of our team which has worked tirelessly over many years to identify this candidate for such a difficult target."
Preclinical Evidence and Development Timeline
In preclinical studies, LQT-23 (搜索) demonstrated selective modulation of the target and robust suppression of somatic expansion in Huntington's disease (搜索) cellular systems and animal models. The compound showed potent and selective modulation of MSH3 (搜索)/MutS𝛽 (搜索) which leads to robust blockade of somatic expansion in these systems.
The company plans to continue preclinical development through 2026 and is aiming to file regulatory submissions to initiate clinical testing later this year. Reynolds described the nomination as reflecting years of work to build disease-relevant assays and identify compounds capable of engaging what he called "an exceptionally challenging target."
Competitive Positioning in Evolving Therapeutic Landscape
The program enters a rapidly evolving field that includes gene therapies and antisense oligonucleotide approaches designed to lower huntingtin protein levels. Several therapeutic leads aim to reduce the production of mutant huntingtin at the DNA or RNA level, either by delivering gene-editing or gene-silencing constructs to neurons using viral vectors or by administering antisense oligonucleotides that bind huntingtin mRNA and suppress its translation through repeated intrathecal dosing.
While these strategies have shown biological activity, their development has been tempered by challenges related to brain-wide delivery, long-term safety, treatment burden and cost. Oral small molecules offer a potentially more flexible and scalable alternative, particularly for long-term treatment or preventive use in individuals who carry the mutant gene but have not yet developed symptoms.
Company Background and Funding
Founded in 2019, LoQus23 focuses on developing oral small-molecule inhibitors of somatic expansion for Huntington's disease (搜索) and related disorders. The company raised £35 million in a Series A financing round in 2024, led by Forbion (搜索) with participation from the Dementia Discovery Fund (搜索) and Novartis Venture Fund (搜索).
Dr. Cyrus Mozayeni, Chair of the Board of Directors of LoQus23, noted: "MSH3 (搜索)/MutS𝛽 (搜索) is the most promising and best validated target for HD, but has been difficult to drug. The team has made exceptional progress since the financing in 2024, and the nomination of LQT-23 (搜索) as our lead development candidate underscores our deep domain expertise."
Huntington's disease (搜索) is an autosomal dominant neurodegenerative disorder (搜索) with 30,000 patients in the US alone. By targeting somatic expansion, LoQus23 aims to slow or even halt the onset and progression of this devastating disease.